Clinical meaning
The prescribing process is a systematic clinical reasoning framework that translates a confirmed diagnosis into a safe, effective, and monitored pharmacotherapeutic plan. It begins with establishing an accurate diagnosis — prescribing without diagnostic certainty leads to masking of serious conditions, therapeutic failure, and unnecessary adverse drug effects. Once the diagnosis is confirmed, the NP selects a drug class based on current clinical practice guidelines (ACC/AHA, ADA, GINA, IDSA) and then chooses a specific agent within that class based on pharmacodynamic principles (mechanism of action matching the pathophysiology), pharmacokinetic suitability (considering the patient's renal function via CKD-EPI eGFR, hepatic function via Child-Pugh classification, age-related changes in body composition and organ function), and patient-specific factors (allergies, comorbidities, pregnancy/lactation status, pharmacogenomic profile, concurrent medications, cost, and adherence barriers). Drug-drug interactions occur through multiple mechanisms: CYP450 enzyme inhibition (e.g., fluconazole inhibiting CYP2C9 and potentiating warfarin bleeding risk), enzyme induction (e.g., rifampin inducing CYP3A4 and reducing oral contraceptive efficacy), protein binding displacement (e.g., valproic acid displacing phenytoin from albumin, increasing free phenytoin and toxicity risk), pharmacodynamic interactions (e.g., additive QTc prolongation from combining fluoroquinolones with antipsychotics), and renal elimination competition (e.g., probenecid blocking tubular secretion of penicillins). Polypharmacy in elderly patients creates exponentially increasing interaction risk and is complicated by age-related pharmacokinetic changes: decreased gastric acid and motility (altered absorption), reduced lean body mass and increased adipose tissue (altered distribution), decreased hepatic blood flow and CYP activity (reduced metabolism), and declining GFR (impaired renal elimination). The Beers Criteria identifies potentially inappropriate medications in adults ≥65 (avoid benzodiazepines, anticholinergics, long-acting sulfonylureas, and nonselective NSAIDs), while the STOPP/START criteria guide both deprescribing and initiation of evidence-based therapies. Therapeutic drug monitoring (TDM) is essential for narrow therapeutic index medications where small changes in serum concentration produce large changes in pharmacological effect: lithium (therapeutic 0.6-1.2, toxic >1.5 mEq/L), digoxin (therapeutic 0.5-2.0, toxic >2.0 ng/mL), vancomycin (trough 15-20 for serious infections), phenytoin (therapeutic 10-20 mcg/mL total, 1-2 free). TDM levels must be drawn at steady state (4-5 half-lives after initiation or dose change) and timed correctly (trough immediately before the next dose). The prescribing process concludes with structured follow-up — monitoring treatment efficacy, screening for adverse effects, reassessing continued indication, and implementing deprescribing when benefits no longer outweigh risks.